Development of tracer-based metabolomics and its implications for the pharmaceutical industry

International Journal of Pharmaceutical Medicine

Volumn 21, Issue 3, 2007, Pages 217-224

  Maguire, Greg ^a   Boros, Laszlo ^a   Lee, Paul ^b  

^a SiDMAP   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONG CHAIN FATTY ACID; TISSUE EXTRACT; TRACER;

ANALYTIC METHOD; AUTOMATION; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INDUSTRY; GENOTYPE; HIGH THROUGHPUT SCREENING; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REVIEW;

EID: 34249774012     PISSN: 13649027     EISSN: 14735679     Source Type: Journal    
DOI: 10.2165/00124363-200721030-00004     Document Type: Review

References (30)

1. Harrigan GG, Goodacre, R, editors. Metabolic profiling: its role in biomarker discovery and gene function analysis. Boston (PA): Kluwer Academic Publishers, 2003
2. Aardema MJ, MacGregor JT. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat Res 2002 Jan 29; 499 (1): 13-25
3. Brown M, Dunn WB, Ellis DI, et al. A metabolome pipeline: from concept to data to knowledge. Metabolomics 2006; 1: 39-51
4. Boros LG, Casacante M, Lee WN. Metabolic profiling of cell growth and death in cancer; applications in drug discovery. Drug Discovery Today 2002; 7: 364-72
5. 13C2] glucose. Am J Physiol 1998; 274: E843-51
6. Lee WNP. Characterizing phenotype with tracer based metabolomics. Metabolomics 2006; 2: 31-9
7. Maguire G, Lee P, Manheim D, et al. SiDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways. Expert Opin Drug Disc 2006; 4: 351-9
8. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and applications to pharmaceutical research and development. Pharm Res 2006; 23: 1075-88
9. Ellis DI, Goodacre R. Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 2006 Aug; 131 (8): 875-885. Epub 2006 Apr 25
10. Lindon JC, Holmes E, Nicholson JK. Metabolomics in pharmaceutical R&D. FEBS J 2007; 274: 1140-51
11. Hollywood K, Briston DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics 2006; 6: 4716-23
12. Causton DR. A biologist's advanced mathematics. London: Allen & Unwin, 1987
13. Manly BFJ. Multivariate statistical methods: a primer. London: Chapman and Hall, 1994
14. Wang Y, Holmes E, Tang H, et al. Experimental metabonomic model of dietary variation and stress interactions. J Proteome Res 2006 Jul; 5 (7): 1535-42
15. Rossell S, van der Weijden CC, Lindenbergh A, et al. Unraveling the complexity of flux regulation: a new method demonstrated for nutrient starvation in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 2006 Feb 14; 103 (7): 2166-71. Epub 2006 Feb 7
16. Fell DA. Understanding the control of metabolism. London: Portland Press, 1996
17. Kell DB, Westerhoff HV. Metabolic control theory: its role in microbiology and biotechnology. FEMS Microbiol Rev 1986; 39: 305-20
18. Bolling C, Fiehn O. Metabolite profiling of Chlamydomonas reinhardtii under nutrient deprivation. Plant Physiol 2005 Dec; 139 (4): 1995-2005. Epub 2005 Nov 23
19. 13C2]glucose. Biochem J 2004 Jul 1; 381 (Pt 1): 287-94
20. Famili I, Palsson BO. Systemic metabolic reactions are obtained by singular value decomposition of genome-scale stoichiometric matrices. J Theor Biol 2003 Sep 7; 224 (1): 87-96
21. Papin S, Cazeneuve C, Duquesnoy P, et al. The tumor necrosis factor alpha-dependent activation of the human Mediterranean fever (MEFV) promoter is mediated by a synergistic interaction between C/EBP beta and NF kappaB p65. J Biol Chem 2003 Dec 5; 278 (49): 48839-47. Epub 2003 Sep 26
22. Reed JL, Palsson BO. Thirteen years of building constraint-based in silico models of Escherichia coli. J Bacteriol 2003 May; 185 (9): 2692-9
23. Boren J, Lee WN, Bassilian S, et al. The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem 2003; 278: 395-402
24. Boros LG, Bassilian S, Lim S, et al. Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. Pancreas 2001 Jan; 22 (1): 1-7
25. Boros LG, Serkova NJ, Cascante MS, et al. Use of metabolic pathway flux information in targeted cancer drug design. Drug Disc Today Ther Strat 2004; 4: 435-43
26. Harrigan GG. Metabolomics: a systems contribution to pharmaceutical discovery and drug development. Drug Disc World 2006 Spring: 39-46
27. Michael LF. Targeting endocrine function of bile acids. IBC Fifth Annual Targeting Metabolic Syndrome; 2007 Feb 26-28; Boston (MA).
28. Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic Acids Res 2007; 35; D521-6
29. Harrigan GG, Colca J, Szalma S, et al. PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: a comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells. Metabolomics 2006; 2 (1): 21-9
30. Raamsdonk LM, Teusink B, Broadhurst D, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nature Biotechnol 2001 Jan; 19 (1): 45-50